Ainos (OTCMKTS:AIMD) & Nova Eye Medical (OTCMKTS:ELXMF) Head to Head Contrast

Earnings and Valuation

This table compares Nova Eye Medical and Ainos”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nova Eye Medical	N/A	N/A	N/A	$0.01	13.70
Ainos	$40,633.00	161.74	-$14.01 million	($2.55)	-0.19

Nova Eye Medical has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than Nova Eye Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.4% of Nova Eye Medical shares are held by institutional investors. Comparatively, 0.3% of Ainos shares are held by institutional investors. 10.4% of Ainos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Nova Eye Medical and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nova Eye Medical	N/A	N/A	N/A
Ainos	-515.80%	-44.32%	-40.35%

Summary

Nova Eye Medical beats Ainos on 6 of the 8 factors compared between the two stocks.

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.